264
agents are considered as potential drug candidates aganist a variety of clinical manifestations. As there is a greater scope for exploration of our vast bioresources in
screening out efficient anti-inflammatory molecules, it has become a prime agenda
for the global pharmaceutical industry.
References
Abramson S, Weissmann G (1981) The release of inflammatory mediators from neutrophils. Ric
Clin Lab 11(2):91–99
Arend WP (2002) The mode of action of cytokine inhibitors. J Rheumatol 65:16–21
Ballanti E, Perricone C, di Muzio G, Kroegler B, Chimenti MS, Graceffa D, Perricone R (2011)
Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with
anti-TNF inhibitors. Autoimmun Rev 10:617–623
Banyer JL, Hamilton NH, Ramshaw IA, Ramsay AJ (2000) Cytokines in innate and adaptive
immunity. Rev Immunogenet 2:359–373
Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G (2007) Nonallergic angiodema:
role of Bradykinin. Allergy 62(8):842–856
Bell SJ, Kamm MA (2000) Review article: the clinical role of anti-TNFalpha antibody treatment
in Crohn’s disease. Aliment Pharmacol Ther 14:501–514
Camp NJ, Cox A, di Giovine FS, McCabe D, Rich W, Duff GW (2005) Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. Genes Immun
6:467–471
Capetti AF, Pocaterra D, Zucchi P, Carenzi L, Rizzardini G (2010) Anti-inflammatory effect of
maraviroc in an HIV-infected patient with concomitant myositis: a case report. J Inter Ass Phys
AIDS Care (Chicago) 9:201–202
Castro Villegas Mdel C, Escudero Contreras A, Miranda Garcia MD, Collantes Estevez E
(2012) How to optimize the anti-TNF alpha therapy in spondylitis? Reumatologia Clinica
8(1):S26–S31
Chagnon M, Gentile J, Gladu M, Sirois P (1985) The mechanism of action of leukotrienes A4, C4
and D4 on human lung parenchyma in vitro. Lung 163:55–62
Clark W, Jobanputra P, Barton P, Burls A (2004) The clinical and cost-effectiveness of anakinra
for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Health Tech Assess 8:iii–iv, ix–x, 1–105
Cook EB (2004) Tear cytokines in acute and chronic ocular allergic inflammation. Curr Opin
Allergy Clin Immunol 4:441–445
D’Ambrosio D, Panina-Bordignon P, Sinigaglia F (2003) Chemokine receptors in inflammation:
an overview. J Immunol Methods 273:3–13
de La Mata LJ, Gonzalez Crespo R, Maese Manzano J (2007) Treatment of rheumatoid arthritis
with anakinra: a systematic review. Reumatol Clinica 3:153–158
Donnelly LE, Barnes PJ (2006) Chemokine receptors as therapeutic targets in chronic obstructive
pulmonary disease. Trends Pharmacol Sci 27:546–553
Du Buske LM (1996) Clinical comparison of histamine H1-receptor antagonist drugs. J Allergy
Clin Immunol 98:S307–S318
Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M (2011) New insights of an old defense system:
structure, function, and clinical relevance of the complement system. Mol Med 17:317–329
El-Asrar AM (2012) Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East
Afr J Ophthal 19:70–74
Elices MJ (2002) BX-471 Berlex. Curr Opin Investig Drugs 3:865–869
Feghali CA, Wright TM (1997) Cytokines in acute and chronic inflammation. Front Biosci
2:d12–d26
B.C. Bhavya and M. Haridas
agents are considered as potential drug candidates aganist a variety of clinical manifestations. As there is a greater scope for exploration of our vast bioresources in
screening out efficient anti-inflammatory molecules, it has become a prime agenda
for the global pharmaceutical industry.
References
Abramson S, Weissmann G (1981) The release of inflammatory mediators from neutrophils. Ric
Clin Lab 11(2):91–99
Arend WP (2002) The mode of action of cytokine inhibitors. J Rheumatol 65:16–21
Ballanti E, Perricone C, di Muzio G, Kroegler B, Chimenti MS, Graceffa D, Perricone R (2011)
Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with
anti-TNF inhibitors. Autoimmun Rev 10:617–623
Banyer JL, Hamilton NH, Ramshaw IA, Ramsay AJ (2000) Cytokines in innate and adaptive
immunity. Rev Immunogenet 2:359–373
Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G (2007) Nonallergic angiodema:
role of Bradykinin. Allergy 62(8):842–856
Bell SJ, Kamm MA (2000) Review article: the clinical role of anti-TNFalpha antibody treatment
in Crohn’s disease. Aliment Pharmacol Ther 14:501–514
Camp NJ, Cox A, di Giovine FS, McCabe D, Rich W, Duff GW (2005) Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. Genes Immun
6:467–471
Capetti AF, Pocaterra D, Zucchi P, Carenzi L, Rizzardini G (2010) Anti-inflammatory effect of
maraviroc in an HIV-infected patient with concomitant myositis: a case report. J Inter Ass Phys
AIDS Care (Chicago) 9:201–202
Castro Villegas Mdel C, Escudero Contreras A, Miranda Garcia MD, Collantes Estevez E
(2012) How to optimize the anti-TNF alpha therapy in spondylitis? Reumatologia Clinica
8(1):S26–S31
Chagnon M, Gentile J, Gladu M, Sirois P (1985) The mechanism of action of leukotrienes A4, C4
and D4 on human lung parenchyma in vitro. Lung 163:55–62
Clark W, Jobanputra P, Barton P, Burls A (2004) The clinical and cost-effectiveness of anakinra
for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Health Tech Assess 8:iii–iv, ix–x, 1–105
Cook EB (2004) Tear cytokines in acute and chronic ocular allergic inflammation. Curr Opin
Allergy Clin Immunol 4:441–445
D’Ambrosio D, Panina-Bordignon P, Sinigaglia F (2003) Chemokine receptors in inflammation:
an overview. J Immunol Methods 273:3–13
de La Mata LJ, Gonzalez Crespo R, Maese Manzano J (2007) Treatment of rheumatoid arthritis
with anakinra: a systematic review. Reumatol Clinica 3:153–158
Donnelly LE, Barnes PJ (2006) Chemokine receptors as therapeutic targets in chronic obstructive
pulmonary disease. Trends Pharmacol Sci 27:546–553
Du Buske LM (1996) Clinical comparison of histamine H1-receptor antagonist drugs. J Allergy
Clin Immunol 98:S307–S318
Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M (2011) New insights of an old defense system:
structure, function, and clinical relevance of the complement system. Mol Med 17:317–329
El-Asrar AM (2012) Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East
Afr J Ophthal 19:70–74
Elices MJ (2002) BX-471 Berlex. Curr Opin Investig Drugs 3:865–869
Feghali CA, Wright TM (1997) Cytokines in acute and chronic inflammation. Front Biosci
2:d12–d26
B.C. Bhavya and M. Haridas